EU/3/18/2056: Orphan designation for the treatment of idiopathic pulmonary fibrosis

(S)-(−)-3-(4-aminophenyl)-2-methoxypropanoic acid

Overview

On 24 August 2018, orphan designation (EU/3/18/2056) was granted by the European Commission to Nogra Pharma Limited, Ireland, for (S)-(−)-3-(4-aminophenyl)-2-methoxypropanoic acid (also known as GED-0507-34-Levo) for the treatment of idiopathic pulmonary fibrosis.

Key facts

Active substance
(S)-(−)-3-(4-aminophenyl)-2-methoxypropanoic acid
Intented use
Treatment of idiopathic pulmonary fibrosis
Orphan designation status
Positive
EU designation number
EU/3/18/2056
Date of designation
24/08/2018
Sponsor

Nogra Pharma Limited
33 Sir John Rogerson's Quay
Dublin 2
Ireland
Tel. +353 87 6203961
E-mail: info@nographarma.com

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating